| 指標 | 当期 | 前年同期 | YoY |
|---|---|---|---|
| Revenue / Net Sales | ¥244.0B | ¥222.8B | +9.5% |
| Operating Income / Operating Profit | ¥74.9B | ¥61.4B | +22.0% |
| Ordinary Income | ¥80.4B | ¥60.3B | +33.3% |
| Net Income / Net Profit | ¥56.4B | ¥42.5B | +32.6% |
| ROE | 9.9% | 7.9% | - |
For the cumulative Q3 results for the fiscal year ending May 2026, Revenue was ¥244.0B (YoY +¥21.2B +9.5%), Operating Income was ¥74.9B (YoY +¥13.5B +22.0%), Ordinary Income was ¥80.4B (YoY +¥20.1B +33.3%), and Net Income attributable to owners of the parent was ¥56.4B (YoY +¥13.9B +32.6%). Revenue increased across all three business segments, Operating Margin improved to 30.7% (prior-year 27.5%) a +3.2pt improvement, and Net Margin expanded to 23.1% (prior-year 19.1%) a +4.0pt increase. Non-operating items included foreign exchange gains of ¥6.6B (prior-year foreign exchange losses of ¥1.1B), which accelerated the increase at the ordinary income level, causing Ordinary Income growth to exceed Operating Income growth by 11.3pt. Cost of sales ratio improved to 33.3% (prior-year 36.0%) a -2.7pt change, and SG&A ratio decreased to 36.0% (prior-year 36.4%) a -0.4pt change, reflecting operating leverage in the profit structure.
[Revenue] The breakdown of Revenue ¥244.0B (+9.5%) is Dental-related products ¥81.0B (+16.3%), Surgical-related products ¥73.9B (+6.0%), and Ailes needle-related products ¥89.0B (+6.8%). Dental showed the highest growth rate, supported by new product launches and recovery in dental market demand. Surgical and Ailes needle maintained mid-single-digit growth, resulting in revenue increases across all segments. Regional detail is not disclosed, but the foreign currency translation adjustment was +¥19.8B (prior-year -¥1.1B), turning strongly positive and indicating that conversion of overseas sales into yen contributed to revenue growth.
[Profitability] Gross profit was ¥162.8B (gross margin 66.7%), up ¥18.3B YoY, with gross margin improving by +2.7pt. Stable raw material prices, improved product mix, and production efficiency contributed to gross margin expansion. SG&A was ¥87.9B (SG&A ratio 36.0%), up ¥6.8B YoY (+8.4%), restrained below the Revenue growth rate of +9.5%, producing Operating Income of ¥74.9B (Operating Margin 30.7%). Non-operating income included interest income ¥1.9B, equity-method investment income ¥0.1B, and foreign exchange gains ¥6.6B; total non-operating income ¥9.7B significantly exceeded non-operating expenses ¥4.2B. Net FX contribution after subtracting FX losses of ¥1.1B was about ¥5.5B, providing roughly a 6.8% uplift to Ordinary Income of ¥80.4B. Extraordinary items were minor at ¥0.2B (gain on disposal of fixed assets ¥0.03B, etc.); Pre-tax Income ¥80.5B less corporate taxes ¥24.1B resulted in Net Income ¥56.4B. The effective tax rate was 30.0%, a standard level. In conclusion, revenue and profit increases were achieved through revenue growth across all segments, improved gross margins and SG&A efficiency driving operating profit growth, and a forex tailwind boosting results at the ordinary income level.
Dental-related products: Revenue ¥81.0B (+16.3%), Operating Income ¥14.7B (+102.3%), Segment Margin 18.2% (prior-year 10.4%) — a substantial improvement. Recovery in dental implant demand and a shift to higher value-added products contributed to margin expansion. Surgical-related products: Revenue ¥73.9B (+6.0%), Operating Income ¥25.6B (+8.3%), Segment Margin 34.6% (prior-year 33.9%) — maintained at a high level. Demand for needles for surgical procedures remained stable, supporting the business as a core profit base. Ailes needle-related products: Revenue ¥89.0B (+6.8%), Operating Income ¥34.5B (+13.4%), Segment Margin 38.8% (prior-year 36.6%) — the highest margin recorded. Technical superiority in suturing needles and penetration in overseas markets continued, making this the largest profit source, accounting for 46.1% of Operating Income. All segments achieved year-over-year increases in revenue and income, with margins generally improving.
[Profitability] Operating Margin 30.7% (prior-year 27.5%), Net Margin 23.1% (prior-year 19.1%) remain at high levels, and ROE improved to 9.9% (prior-year 8.0%). Gross Margin 66.7% (prior-year 64.0%) expanded +2.7pt due to product mix improvement and cost efficiency; SG&A ratio 36.0% (prior-year 36.4%) improved -0.4pt due to operating leverage as Revenue expanded. EBIT margin 30.7% is at the same level as Operating Margin; with minimal financial costs, business profitability directly drives the financial structure. [Cash Quality] Of non-operating income ¥9.7B, foreign exchange gains ¥6.6B were the largest component, but remain 2.7% of Revenue, indicating the bulk of Ordinary Income is generated from operating activities. Interest income ¥1.9B reflects accumulated cash and deposits of ¥237.6B (prior-year ¥184.2B), equivalent to an annualized cash yield of about 0.8%. [Investment Efficiency] Total asset turnover was 0.39x (annualized 0.78x), basically unchanged from prior-year 0.38x; increases in cash and inventories suppressed asset turnover. Inventories ¥66.7B (prior-year ¥64.2B) are led by work-in-progress ¥31.9B, with finished goods ¥9.4B and raw materials ¥25.4B; inventory management refinement is a focus to improve asset efficiency. [Financial Soundness] Equity Ratio 91.6% (prior-year 92.4%) remains very high, with Total Assets ¥624.7B and Net Assets ¥572.4B; interest-bearing debt is effectively zero (only lease liabilities), indicating a debt-free operation. Current Ratio 803.9% (Current Assets ¥343.7B / Current Liabilities ¥42.8B) and Quick Ratio 781.8% indicate robust short-term liquidity, with cash and deposits ¥237.6B covering current liabilities about 5.6 times.
As the cash flow statement is not disclosed, funding trends are analyzed from the balance sheet movements. Cash and deposits increased to ¥237.6B (prior-year ¥184.2B), up ¥53.4B, indicating most of the Net Income ¥56.4B was retained in cash. Current assets increased to ¥343.7B (prior-year ¥299.8B), up ¥43.9B, composed of Cash +¥53.4B, Accounts Receivable +¥1.0B (¥29.5B), Inventories +¥2.5B (¥66.7B, mainly WIP +¥4.6B). Fixed assets were ¥281.1B (prior-year ¥280.1B), essentially flat; tangible fixed assets ¥255.2B (prior-year ¥257.6B) slightly decreased as depreciation exceeded capital expenditures, and investment securities rose to ¥3.0B (prior-year ¥0.6B) up ¥2.4B. Liabilities increased to ¥52.3B (prior-year ¥44.3B), up ¥8.0B; current liabilities rose to ¥42.8B (prior-year ¥34.9B), up ¥7.9B, mainly due to increases in unpaid corporate taxes ¥11.9B (prior-year ¥10.9B) and other current liabilities ¥18.9B (prior-year ¥11.0B) offsetting a decrease in accounts payable ¥2.1B (prior-year ¥2.5B). Net assets increased to ¥572.4B (prior-year ¥535.6B), up ¥36.8B; retained earnings increased to ¥506.3B (prior-year ¥489.3B) up ¥17.0B (corresponding to Net Income ¥56.4B less interim dividend ¥17.0B × approx. 98,502 thousand shares ≒ ¥16.7B), and foreign currency translation adjustment increased to ¥74.6B (prior-year ¥54.8B) up ¥19.8B. Funding trends show that most operating profits are retained as cash, and cash accumulation continues even after dividend payments, leaving very high capacity for growth investment and shareholder returns.
The difference between Ordinary Income ¥80.4B and Operating Income ¥74.9B is non-operating income ¥9.7B less non-operating expenses ¥4.2B = +¥5.5B, mainly due to temporary factors: foreign exchange gains ¥6.6B and interest income ¥1.9B. FX gains stem from yen depreciation during the period affecting foreign-currency-denominated assets and sales translation, and carry reversal risk with future FX movements. Non-operating income ¥9.7B represents 4.0% of Revenue, so the bulk of Ordinary Income is generated from operating activities. Extraordinary items were minor at ¥0.2B (gain on disposal of fixed assets ¥0.03B, etc.), with a temporary impact of less than 0.4% on Net Income ¥56.4B. The difference between Comprehensive Income ¥76.2B and Net Income ¥56.4B (¥19.8B) is due to the increase in foreign currency translation adjustments, which is an accounting valuation gain when converting overseas subsidiaries' net assets into yen and is an OCI item not accompanied by cash inflow. The effective tax rate of 30.0% is standard, with no observed temporary tax items. Earnings quality is primarily driven by operating improvements, with non-operating items like FX and interest income being secondary. While attention is warranted on the sustainability of FX gains, structured improvements in gross margins and operating leverage indicate a structural enhancement in earnings quality.
Full Year / FY plan: Revenue ¥329.0B (YoY +9.8%), Operating Income ¥97.0B (YoY +18.4%), Ordinary Income ¥101.5B (YoY +22.7%), Net Income ¥68.0B. Q3 cumulative progress ratios versus the full year plan are: Revenue 74.2% (244.0/329.0), Operating Income 77.2% (74.9/97.0), Ordinary Income 79.2% (80.4/101.5), Net Income 83.0% (56.4/68.0). Compared with a standard Q3 progress of 75%, Revenue is roughly on plan, Operating Income is +2.2pt ahead, Ordinary Income +4.2pt ahead, and Net Income +8.0pt ahead. The Net Income outperformance is due to FX gains and better-than-expected gross margin improvements. Q4 standalone is planned as Revenue ¥85.0B (YoY +17.6%), Operating Income ¥22.1B (YoY +1.9%), Ordinary Income ¥21.1B (YoY -9.3%), Net Income ¥11.6B (YoY -17.0%). The slowdown in operating profit growth for Q4 and the projected declines in Ordinary and Net Income likely reflect the wind-down of the FX tailwind and conservative assumptions at the start of the fiscal year. Management has revised earnings forecasts this quarter, and the probability of achieving full-year guidance is considered high.
An interim dividend of ¥17 per share has been paid (prior-year ¥16), and the full-year dividend forecast remains ¥24 per share (prior-year ¥24) unchanged. The year-end dividend is expected at ¥7 per share (prior-year ¥8). Against Q3 Net Income ¥56.4B, the interim dividend total is approximately ¥16.7B (¥17 × 98,502千株), giving an interim payout ratio of 29.6%. Against the full-year Net Income forecast ¥68.0B, total annual dividends are approximately ¥23.6B (¥24 × 98,502千株), implying a full-year payout ratio of 34.7%, a conservative level. With cash and deposits ¥237.6B and a debt-free balance sheet, the capacity to secure dividend funding is very high. There is no revision to the dividend forecast and a stable dividend policy is maintained. No share buyback has been disclosed; shareholder returns are focused on dividends.
FX fluctuation risk: FX gains ¥6.6B (approximately 8.2% of Ordinary Income) drove the increase at the ordinary income level, but a yen appreciation in subsequent periods could turn non-operating items into a headwind and reduce Ordinary Income. The foreign currency translation adjustment of +¥19.8B (26.0% of Comprehensive Income) is a source of net asset valuation volatility, and FX sensitivity is moderate. No hedging policy disclosure was provided, so resilience to FX volatility is limited.
Inventory management risk: Of inventories ¥66.7B (10.7% of Total Assets), work-in-progress ¥31.9B (47.8%) is the largest component, suggesting long production lead times and complex process control. A high WIP ratio entails risks of inventory obsolescence and write-downs under demand fluctuations, potentially impacting gross margins. Optimization of working capital, including raw materials ¥25.4B and finished goods ¥9.4B, is a priority.
Concentration of earnings risk: Ailes needle-related products account for 46.1% of Operating Income (¥34.5/¥74.9B), indicating high profit dependence on a single segment. If that segment experiences market deterioration or intensified competition, the effect on consolidated profits could be significant; diversification of the portfolio through expanded contributions from Dental and Surgical is key to medium- to long-term earnings stability.
Profitability & Return
| 指標 | 自社 | 中央値 (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 30.7% | 8.9% (5.4%–12.7%) | +21.8pt |
| Net Margin | 23.1% | 6.5% (3.3%–9.4%) | Delta |
Profitability substantially exceeds the manufacturing median, reflecting high value-added products and technological superiority.
Growth & Capital Efficiency
| 指標 | 自社 | 中央値 (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 9.5% | 2.8% (-1.5%–8.8%) | +6.7pt |
Growth rate exceeds the industry median by +6.7pt, confirming expanding product demand and market share.
※Source: Company compilation
Expansion of Operating Margin to 30.7% (+3.2pt) and Net Margin to 23.1% (+4.0pt) indicates structural profitability improvement driven by product mix optimization and operating leverage. Gross Margin 66.7% reflects technological advantage and strong pricing power, well above manufacturing benchmarks. FX gains ¥6.6B are temporary, but the core operating profit increase of ¥13.5B (Operating Income YoY) is the main driver, indicating high quality of earnings.
Equity Ratio 91.6% and Cash and Deposits ¥237.6B (38.0% of Total Assets) indicate very strong financial capacity, providing wide options for growth investment, M&A, and dividend increases. With effectively zero interest-bearing debt and no interest burden, improving ROE from 9.9% depends on capital efficiency measures (share buybacks, higher dividends, accelerated growth investment). The payout ratio 34.7% is conservative, and given the pace of cash accumulation there is scope to strengthen shareholder returns.
Improving working capital efficiency, particularly inventories ¥66.7B (notably WIP ¥31.9B), is the next value creation driver. Reducing WIP through shorter production lead times and enhanced process control could accelerate the cash conversion cycle and further boost free cash generation. The probability of achieving full-year guidance is high, and Q3 progress of 83.0% (Net Income) indicates front-loading due to FX and margin improvements.
This report is an earnings analysis document automatically generated by AI based on XBRL financial statement data. It does not constitute a recommendation to invest in any specific security. Industry benchmarks are reference information compiled by the Company based on public financial statements. Investment decisions are your own responsibility; consult a professional if necessary before proceeding.